Form 4: CRISPR Therapeutics CMO Executes RSU Vesting and Tax Sale
Statement of Changes in Beneficial Ownership
Chief Medical Officer Naimish Patel acquired 10,000 shares via RSU vesting and sold 3,786 shares to cover tax obligations.
Summary
- Naimish Patel, Chief Medical Officer of CRISPR Therapeutics, exercised 10,000 restricted stock units (RSUs) on May 28, 2026.
- Following the vesting, 3,786 shares were sold on May 29, 2026, at a price of $55.62 per share.
- The sale was executed to satisfy mandatory tax withholding obligations under the company's RSU settlement policy.
- The reporting person retains 19,357 shares following these transactions.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as the transaction was purely administrative and non-discretionary.
Positives
- The transaction reflects the scheduled vesting of equity compensation, indicating ongoing alignment between executive incentives and company performance.
Negatives
- None identified; the sale was a non-discretionary transaction required for tax compliance.
Risks
- None identified; this is a routine regulatory disclosure regarding executive compensation.
Future Outlook
The remaining 20,000 restricted stock units are scheduled to vest in equal installments on May 28, 2027, and May 28, 2028.
Industry Context
StockSavvy.ai notes that mandatory tax-related share sales by executives are standard industry practice in the biotechnology sector and do not typically signal a change in management sentiment regarding company prospects.
Comparison to Industry Standards
- The transaction follows standard corporate governance protocols for RSU settlement.
- The use of a mandatory sell-to-cover policy is consistent with practices at other large-cap biotech firms like Vertex Pharmaceuticals and Intellia Therapeutics.
Stakeholder Impact
- No material impact on shareholders or company operations.
Next Steps
- Future vesting of remaining 20,000 RSUs scheduled for May 2027 and May 2028.
Key Dates
| Date | Description |
|---|---|
| 05/28/2026 | Vesting of 10,000 restricted stock units. |
| 05/29/2026 | Sale of 3,786 shares to cover tax withholding obligations. |
| 06/01/2026 | Filing date of the Form 4. |
Keywords
CRISPR Therapeutics, CRSP, Insider Trading, Form 4, Biotech, Executive Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.